Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acceptability study of a new paediatric formulation of Orphacol (cholic acid) in paediatric patients treated for inborn errors in primary bile acid synthesis due to 3ß-Hydroxy-5-C27- steroid oxidoreductase deficiency or 4-3-Oxosteroid-5ß-reductase deficiency-ORPH-PAED-01

Trial Profile

Acceptability study of a new paediatric formulation of Orphacol (cholic acid) in paediatric patients treated for inborn errors in primary bile acid synthesis due to 3ß-Hydroxy-5-C27- steroid oxidoreductase deficiency or 4-3-Oxosteroid-5ß-reductase deficiency-ORPH-PAED-01

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jul 2018

At a glance

  • Drugs Cholic acid (Primary)
  • Indications Inborn genetic disorders; Liver disorders
  • Focus Therapeutic Use
  • Acronyms ORPH-PAED-01
  • Most Recent Events

    • 30 Jul 2018 Status changed from active, no longer recruiting to completed.
    • 22 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top